首页 > 最新文献

Asia Pacific Allergy最新文献

英文 中文
From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events. 从肿瘤到耐受:全面回顾免疫检查点抑制剂和免疫相关不良事件。
IF 1.6 Q3 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-05-30 DOI: 10.5415/apallergy.0000000000000146
Henry Sutanto, Ardea Safira, Deasy Fetarayani

The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for various malignancies by harnessing the body's immune system to target cancer cells. However, their widespread use has unveiled a spectrum of immune-related adverse events, highlighting a critical balance between antitumor immunity and autoimmunity. This review article delves into the molecular immunology of ICIs, mapping the journey from their therapeutic action to the unintended induction of immune-related adverse events. We provide a comprehensive overview of all available ICIs, including cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, programmed death-ligand 1 inhibitors, and emerging targets, discussing their mechanisms of action, clinical applications, and the molecular underpinnings of associated immune-related adverse events. Special attention is given to the activation of autoreactive T cells, B cells, cytokine release, and the inflammatory cascade, which together contribute to the development of immune-related adverse events. Through a molecular lens, we explore the clinical manifestations of immune-related adverse events across organ systems, offering insights into diagnosis, management, and strategies to mitigate these adverse effects. The review underscores the importance of understanding the delicate interplay between enhancing antitumor responses and minimizing immune-related adverse events, aiming to guide future research and the development of next-generation ICIs with improved drug safety profiles.

免疫检查点抑制剂(ICIs)通过利用人体免疫系统靶向癌细胞,彻底改变了各种恶性肿瘤的治疗格局。然而,它们的广泛应用也揭示了一系列与免疫相关的不良事件,凸显了抗肿瘤免疫与自身免疫之间的关键平衡。这篇综述文章深入探讨了 ICIs 的分子免疫学,描绘了 ICIs 从治疗作用到意外诱发免疫相关不良事件的全过程。我们全面概述了所有可用的 ICIs,包括细胞毒性 T 淋巴细胞相关蛋白 4、程序性细胞死亡蛋白 1、程序性死亡配体 1 抑制剂和新兴靶点,讨论了它们的作用机制、临床应用以及相关免疫相关不良反应的分子基础。我们特别关注自身反应性 T 细胞、B 细胞的激活、细胞因子的释放和炎症级联反应,这些因素共同导致了免疫相关不良事件的发生。通过分子视角,我们探讨了免疫相关不良事件在各器官系统中的临床表现,为诊断、管理和减轻这些不良反应的策略提供了见解。这篇综述强调了了解增强抗肿瘤反应和减少免疫相关不良事件之间微妙相互作用的重要性,旨在指导未来的研究和开发具有更好药物安全性的下一代 ICIs。
{"title":"From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events.","authors":"Henry Sutanto, Ardea Safira, Deasy Fetarayani","doi":"10.5415/apallergy.0000000000000146","DOIUrl":"10.5415/apallergy.0000000000000146","url":null,"abstract":"<p><p>The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for various malignancies by harnessing the body's immune system to target cancer cells. However, their widespread use has unveiled a spectrum of immune-related adverse events, highlighting a critical balance between antitumor immunity and autoimmunity. This review article delves into the molecular immunology of ICIs, mapping the journey from their therapeutic action to the unintended induction of immune-related adverse events. We provide a comprehensive overview of all available ICIs, including cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, programmed death-ligand 1 inhibitors, and emerging targets, discussing their mechanisms of action, clinical applications, and the molecular underpinnings of associated immune-related adverse events. Special attention is given to the activation of autoreactive T cells, B cells, cytokine release, and the inflammatory cascade, which together contribute to the development of immune-related adverse events. Through a molecular lens, we explore the clinical manifestations of immune-related adverse events across organ systems, offering insights into diagnosis, management, and strategies to mitigate these adverse effects. The review underscores the importance of understanding the delicate interplay between enhancing antitumor responses and minimizing immune-related adverse events, aiming to guide future research and the development of next-generation ICIs with improved drug safety profiles.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 3","pages":"124-138"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of cross-reactive IgE-binding proteins from Philippine allergenic grass pollen extracts. 从菲律宾过敏草花粉提取物中鉴定交叉反应 IgE 结合蛋白。
IF 1.6 Q3 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-08-05 DOI: 10.5415/apallergy.0000000000000155
Mary Anne R Castor, Maria Katrina Diana M Cruz, Gregg Austine M Balanag, Krystal M Hate, Roche Dana C Reyes, Maria Socorro Agcaoili-De Jesus, Cherie C Ocampo-Cervantes, Leslie Michelle M Dalmacio

Background: Respiratory allergies are one of the most common allergic diseases that affect Filipinos. Grass pollen accounts for the majority of the outdoor allergens triggering these respiratory allergies. Cross-reactivity among the Philippine grass pollen grains has not been extensively studied.

Objective: This study aims to investigate the cross-reactivity of our local grasses and identify the cross-reactive allergens.

Methods: Grass pollen grains were collected and processed into crude allergenic extracts. The IgE-reactivity of these crude allergenic pollen extracts was studied using sera from patients who tested positive for the mentioned extracts. The proteins from the immunoblots of cross-reactive pollen allergen extracts were sequenced and identified.

Results: Allergenic pollen proteins were identified as cross-reactive among the grass pollen extracts. Four of these have not been listed yet as grass allergens in the World Health Organization/International Union of Immunological Societies allergen nomenclature database.

Conclusion: Local grass pollen allergens are cross-reactive with probable new allergens identified.

背景:呼吸道过敏是菲律宾人最常见的过敏性疾病之一。草花粉是引发这些呼吸道过敏的大部分室外过敏原。菲律宾草花粉颗粒之间的交叉反应尚未得到广泛研究:本研究旨在调查本地草的交叉反应性,并确定交叉反应过敏原:方法:收集草花粉粒并加工成粗过敏原提取物。使用对上述提取物检测呈阳性的患者血清研究这些粗致敏性花粉提取物的 IgE 反应性。对交叉反应花粉过敏原提取物免疫印迹中的蛋白质进行了测序和鉴定:结果:在草花粉提取物中发现了具有交叉反应性的花粉过敏原蛋白质。结果:在草花粉提取物中发现了具有交叉反应性的致敏花粉蛋白,其中四种尚未被世界卫生组织/国际免疫学会联盟过敏原命名数据库列为草过敏原:结论:本地草花粉过敏原与新发现的可能过敏原存在交叉反应。
{"title":"Identification of cross-reactive IgE-binding proteins from Philippine allergenic grass pollen extracts.","authors":"Mary Anne R Castor, Maria Katrina Diana M Cruz, Gregg Austine M Balanag, Krystal M Hate, Roche Dana C Reyes, Maria Socorro Agcaoili-De Jesus, Cherie C Ocampo-Cervantes, Leslie Michelle M Dalmacio","doi":"10.5415/apallergy.0000000000000155","DOIUrl":"10.5415/apallergy.0000000000000155","url":null,"abstract":"<p><strong>Background: </strong>Respiratory allergies are one of the most common allergic diseases that affect Filipinos. Grass pollen accounts for the majority of the outdoor allergens triggering these respiratory allergies. Cross-reactivity among the Philippine grass pollen grains has not been extensively studied.</p><p><strong>Objective: </strong>This study aims to investigate the cross-reactivity of our local grasses and identify the cross-reactive allergens.</p><p><strong>Methods: </strong>Grass pollen grains were collected and processed into crude allergenic extracts. The IgE-reactivity of these crude allergenic pollen extracts was studied using sera from patients who tested positive for the mentioned extracts. The proteins from the immunoblots of cross-reactive pollen allergen extracts were sequenced and identified.</p><p><strong>Results: </strong>Allergenic pollen proteins were identified as cross-reactive among the grass pollen extracts. Four of these have not been listed yet as grass allergens in the World Health Organization/International Union of Immunological Societies allergen nomenclature database.</p><p><strong>Conclusion: </strong>Local grass pollen allergens are cross-reactive with probable new allergens identified.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 3","pages":"108-117"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New-onset autoimmune thyroid disease following COVID-19. COVID-19 后新发自身免疫性甲状腺疾病。
IF 1.6 Q3 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-05-30 DOI: 10.5415/apallergy.0000000000000145
Öner Özdemir
{"title":"New-onset autoimmune thyroid disease following COVID-19.","authors":"Öner Özdemir","doi":"10.5415/apallergy.0000000000000145","DOIUrl":"10.5415/apallergy.0000000000000145","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 3","pages":"151"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategic testing following toxic epidermal necrolysis allows reintroduction of chemotherapy in a patient with progressive myeloma. 在发生毒性表皮坏死后进行策略性检测,可使进展期骨髓瘤患者重新接受化疗。
IF 1.7 Q3 ALLERGY Pub Date : 2024-06-01 Epub Date: 2023-12-18 DOI: 10.5415/apallergy.0000000000000125
Daniel Soon Lee Goh, Ramon Yuson, Praveen Gounder, James Yun, Sandhya Limaye

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome belong to a family of severe cutaneous adverse reactions that can be life-threatening and carry a risk of significant morbidity and potential mortality in the event of re-exposure. Lifelong avoidance of the culprit agent is mandated, which can lead to the exclusion of multiple medications if the trigger is unclear. This can result in adverse health outcomes analogous to that of a penicillin allergy label. We present a case in which the patient would progress to fatal myeloma in the absence of treatment, however, multiple medications were administered prior to the occurrence of TEN following previous chemotherapy. Available risk stratification tools including human leucocyte antigen assessment and the algorithm of drug causality for epidermal necrolysis scoring system were utilized followed by patch testing which identified a lesser-suspected agent as possibly causative. Further evidence-based in vivo testing and subsequent challenges allowed for the reintroduction of life-saving chemotherapy.

中毒性表皮坏死溶解症(TEN)和史蒂文斯-约翰逊综合征属于严重皮肤不良反应的一种,可危及生命,再次接触时有可能导致严重的发病和死亡。必须终生避免接触致病因子,如果诱发因素不明确,可能会导致多种药物被禁用。这可能会导致类似青霉素过敏标签的不良健康后果。在我们介绍的病例中,患者在未接受治疗的情况下会发展为致命的骨髓瘤,但在之前的化疗后出现 TEN 之前曾服用过多种药物。我们使用了现有的风险分层工具,包括人类白细胞抗原评估和表皮坏死症药物因果关系评分系统算法,然后进行了斑贴试验,结果发现一种不太可疑的药物可能是致病因素。基于证据的进一步活体测试和随后的挑战使挽救生命的化疗得以重新开始。
{"title":"Strategic testing following toxic epidermal necrolysis allows reintroduction of chemotherapy in a patient with progressive myeloma.","authors":"Daniel Soon Lee Goh, Ramon Yuson, Praveen Gounder, James Yun, Sandhya Limaye","doi":"10.5415/apallergy.0000000000000125","DOIUrl":"10.5415/apallergy.0000000000000125","url":null,"abstract":"<p><p>Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome belong to a family of severe cutaneous adverse reactions that can be life-threatening and carry a risk of significant morbidity and potential mortality in the event of re-exposure. Lifelong avoidance of the culprit agent is mandated, which can lead to the exclusion of multiple medications if the trigger is unclear. This can result in adverse health outcomes analogous to that of a penicillin allergy label. We present a case in which the patient would progress to fatal myeloma in the absence of treatment, however, multiple medications were administered prior to the occurrence of TEN following previous chemotherapy. Available risk stratification tools including human leucocyte antigen assessment and the algorithm of drug causality for epidermal necrolysis scoring system were utilized followed by patch testing which identified a lesser-suspected agent as possibly causative. Further evidence-based in vivo testing and subsequent challenges allowed for the reintroduction of life-saving chemotherapy.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 2","pages":"90-92"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11142759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual anaphylaxis induced by food allergen inhalation or skin contact. 食物过敏原吸入或皮肤接触引起的异常过敏性休克。
IF 1.7 Q3 ALLERGY Pub Date : 2024-06-01 Epub Date: 2023-10-09 DOI: 10.5415/apallergy.0000000000000118
Nan Nan Jiang, Li Xiang, Hui Jie Huang, Xiao Ling Hou
{"title":"Unusual anaphylaxis induced by food allergen inhalation or skin contact.","authors":"Nan Nan Jiang, Li Xiang, Hui Jie Huang, Xiao Ling Hou","doi":"10.5415/apallergy.0000000000000118","DOIUrl":"10.5415/apallergy.0000000000000118","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 2","pages":"93-96"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11142753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence applications in allergic rhinitis diagnosis: Focus on ensemble learning. 人工智能在过敏性鼻炎诊断中的应用:聚焦集合学习。
IF 1.7 Q3 ALLERGY Pub Date : 2024-06-01 Epub Date: 2023-12-18 DOI: 10.5415/apallergy.0000000000000126
Dai Fu, Zhao Chuanliang, Yang Jingdong, Meng Yifei, Tan Shiwang, Qian Yue, Yu Shaoqing

Background: The diagnosis of allergic rhinitis (AR) primarily relies on symptoms and laboratory examinations. Due to limitations in outpatient settings, certain tests such as nasal provocation tests and nasal secretion smear examinations are not routinely conducted. Although there are clear diagnostic criteria, an accurate diagnosis still requires the expertise of an experienced doctor, considering the patient's medical history and conducting examinations. However, differences in physician knowledge and limitations of examination methods can result in variations in diagnosis.

Objective: Artificial intelligence is a significant outcome of the rapid advancement in computer technology today. This study aims to present an intelligent diagnosis and detection method based on ensemble learning for AR.

Method: We conducted a study on AR cases and 7 other diseases exhibiting similar symptoms, including rhinosinusitis, chronic rhinitis, upper respiratory tract infection, etc. Clinical data, encompassing medical history, clinical symptoms, allergen detection, and imaging, was collected. To develop an effective classifier, multiple models were employed to train on the same batch of data. By utilizing ensemble learning algorithms, we obtained the final ensemble classifier known as adaptive random forest-out of bag-easy ensemble (ARF-OOBEE). In order to perform comparative experiments, we selected 5 commonly used machine learning classification algorithms: Naive Bayes, support vector machine, logistic regression, multilayer perceptron, deep forest (GC Forest), and extreme gradient boosting (XGBoost).To evaluate the prediction performance of AR samples, various parameters such as precision, sensitivity, specificity, G-mean, F1-score, and area under the curve (AUC) of the receiver operating characteristic curve were jointly employed as evaluation indicators.

Results: We compared 7 classification models, including probability models, tree models, linear models, ensemble models, and neural network models. The ensemble classification algorithms, namely ARF-OOBEE and GC Forest, outperformed the other algorithms in terms of the comprehensive classification evaluation index. The accuracy of G-mean and AUC parameters improved by nearly 2% when compared to the other algorithms. Moreover, these ensemble classifiers exhibited excellent performance in handling large-scale data and unbalanced samples.

Conclusion: The ARF-OOBEE ensemble learning model demonstrates strong generalization performance and comprehensive classification abilities, making it suitable for effective application in auxiliary AR diagnosis.

背景:过敏性鼻炎(AR)的诊断主要依靠症状和实验室检查。由于门诊环境的限制,某些检查如鼻激发试验和鼻分泌物涂片检查并不是常规检查。虽然有明确的诊断标准,但准确的诊断仍需要经验丰富的医生通过考虑患者的病史和进行检查来获得。然而,医生知识的差异和检查方法的局限性会导致诊断结果的差异:人工智能是当今计算机技术飞速发展的重要成果。本研究旨在提出一种基于集合学习的 AR 智能诊断和检测方法:方法:我们对 AR 病例和其他 7 种症状相似的疾病(包括鼻炎、慢性鼻炎、上呼吸道感染等)进行了研究。我们收集了包括病史、临床症状、过敏原检测和影像学在内的临床数据。为了开发有效的分类器,采用了多个模型对同一批数据进行训练。通过使用集合学习算法,我们得到了最终的集合分类器,即自适应随机森林-袋易集合(ARF-OOBEE)。为了进行对比实验,我们选择了 5 种常用的机器学习分类算法:为了评估AR样本的预测性能,我们联合使用了精度、灵敏度、特异性、G均值、F1得分和接收者工作特征曲线下面积(AUC)等各种参数作为评估指标:我们比较了 7 种分类模型,包括概率模型、树模型、线性模型、集合模型和神经网络模型。在综合分类评价指标方面,ARF-OOBEE 和 GC Forest 等集合分类算法优于其他算法。与其他算法相比,G-mean 和 AUC 参数的准确率提高了近 2%。此外,这些集合分类器在处理大规模数据和不平衡样本时表现出色:ARF-OOBEE集合学习模型具有很强的泛化性能和综合分类能力,适合在AR辅助诊断中有效应用。
{"title":"Artificial intelligence applications in allergic rhinitis diagnosis: Focus on ensemble learning.","authors":"Dai Fu, Zhao Chuanliang, Yang Jingdong, Meng Yifei, Tan Shiwang, Qian Yue, Yu Shaoqing","doi":"10.5415/apallergy.0000000000000126","DOIUrl":"10.5415/apallergy.0000000000000126","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis of allergic rhinitis (AR) primarily relies on symptoms and laboratory examinations. Due to limitations in outpatient settings, certain tests such as nasal provocation tests and nasal secretion smear examinations are not routinely conducted. Although there are clear diagnostic criteria, an accurate diagnosis still requires the expertise of an experienced doctor, considering the patient's medical history and conducting examinations. However, differences in physician knowledge and limitations of examination methods can result in variations in diagnosis.</p><p><strong>Objective: </strong>Artificial intelligence is a significant outcome of the rapid advancement in computer technology today. This study aims to present an intelligent diagnosis and detection method based on ensemble learning for AR.</p><p><strong>Method: </strong>We conducted a study on AR cases and 7 other diseases exhibiting similar symptoms, including rhinosinusitis, chronic rhinitis, upper respiratory tract infection, etc. Clinical data, encompassing medical history, clinical symptoms, allergen detection, and imaging, was collected. To develop an effective classifier, multiple models were employed to train on the same batch of data. By utilizing ensemble learning algorithms, we obtained the final ensemble classifier known as adaptive random forest-out of bag-easy ensemble (ARF-OOBEE). In order to perform comparative experiments, we selected 5 commonly used machine learning classification algorithms: Naive Bayes, support vector machine, logistic regression, multilayer perceptron, deep forest (GC Forest), and extreme gradient boosting (XGBoost).To evaluate the prediction performance of AR samples, various parameters such as precision, sensitivity, specificity, G-mean, F1-score, and area under the curve (AUC) of the receiver operating characteristic curve were jointly employed as evaluation indicators.</p><p><strong>Results: </strong>We compared 7 classification models, including probability models, tree models, linear models, ensemble models, and neural network models. The ensemble classification algorithms, namely ARF-OOBEE and GC Forest, outperformed the other algorithms in terms of the comprehensive classification evaluation index. The accuracy of G-mean and AUC parameters improved by nearly 2% when compared to the other algorithms. Moreover, these ensemble classifiers exhibited excellent performance in handling large-scale data and unbalanced samples.</p><p><strong>Conclusion: </strong>The ARF-OOBEE ensemble learning model demonstrates strong generalization performance and comprehensive classification abilities, making it suitable for effective application in auxiliary AR diagnosis.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 2","pages":"56-62"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11142760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer. 一名越南非小细胞肺癌患者因彭博利珠单抗诱发史蒂文斯-约翰逊综合征/毒性表皮坏死溶解症。
IF 1.7 Q3 ALLERGY Pub Date : 2024-06-01 Epub Date: 2023-12-18 DOI: 10.5415/apallergy.0000000000000131
Yen T H Pham, Mai T Vu, Anh Q Nguyen, Phat N Trinh, Mai H Tran, Hieu C Chu, Nguyet T M Nguyen, Chi H V Vu, Dinh V Nguyen

Chemoimmunotherapy is an effective therapy for an individual with nonsmall-cell lung cancer (NSCLC) without anaplastic lymphoma kinase or epidermal growth factor receptor mutations. However, it can also be related to adverse cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with high morbidities and mortality rates. We present a case of a 65-year-old male with NSCLC who underwent first-line chemotherapy with paclitaxel, carboplatin, and pembrolizumab, which was later followed by a second cycle of the same therapies. The patient developed a fever and rash 12 days after the second cycle. Pembrolizumab was strongly suspected as the culprit medication because cutaneous reactions to this drug have been frequently reported and threw other medications used as less likely candidates. This is the first case reported in Vietnam of SJS/TEN related to pembrolizumab and contributes to our knowledge of severe skin reactions associated with immune checkpoint inhibitors.

化疗免疫疗法对于没有发生无性淋巴瘤激酶或表皮生长因子受体突变的非小细胞肺癌(NSCLC)患者来说是一种有效的疗法。然而,免疫疗法也可能导致皮肤不良反应,如史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死(TEN),发病率和死亡率都很高。我们报告了一例 65 岁男性 NSCLC 患者的病例,他接受了紫杉醇、卡铂和彭博利珠单抗的一线化疗,随后又接受了相同疗法的第二周期化疗。患者在第二周期化疗后 12 天出现发热和皮疹。彭博利珠单抗被强烈怀疑是罪魁祸首,因为该药的皮肤反应屡见报道,而其他药物的反应可能性较低。这是越南报告的首例与 Pembrolizumab 相关的 SJS/TEN 病例,有助于我们了解与免疫检查点抑制剂相关的严重皮肤反应。
{"title":"Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer.","authors":"Yen T H Pham, Mai T Vu, Anh Q Nguyen, Phat N Trinh, Mai H Tran, Hieu C Chu, Nguyet T M Nguyen, Chi H V Vu, Dinh V Nguyen","doi":"10.5415/apallergy.0000000000000131","DOIUrl":"10.5415/apallergy.0000000000000131","url":null,"abstract":"<p><p>Chemoimmunotherapy is an effective therapy for an individual with nonsmall-cell lung cancer (NSCLC) without anaplastic lymphoma kinase or epidermal growth factor receptor mutations. However, it can also be related to adverse cutaneous reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with high morbidities and mortality rates. We present a case of a 65-year-old male with NSCLC who underwent first-line chemotherapy with paclitaxel, carboplatin, and pembrolizumab, which was later followed by a second cycle of the same therapies. The patient developed a fever and rash 12 days after the second cycle. Pembrolizumab was strongly suspected as the culprit medication because cutaneous reactions to this drug have been frequently reported and threw other medications used as less likely candidates. This is the first case reported in Vietnam of SJS/TEN related to pembrolizumab and contributes to our knowledge of severe skin reactions associated with immune checkpoint inhibitors.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 2","pages":"84-89"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11142754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis. 杜匹鲁单抗对常染色体显性高免疫球蛋白 E 综合征伴严重特应性皮炎的治疗效果。
IF 1.7 Q3 ALLERGY Pub Date : 2024-03-01 Epub Date: 2023-10-09 DOI: 10.5415/apallergy.0000000000000121
Weifeng Li, Qiqi Qi, Weipeng Wang, Dongqin Li

Hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease characterized by atopic dermatitis, recurrent skin and lung infections, and significantly elevated serum immunoglobulin E levels. Autosomal dominant and loss-of-function pathogenic variants in the STAT3 gene are the most common causes of the disease and studies have shown that the presence of IL-4 receptor (IL-4R) is upregulated in patients with dominant-negative mutations in the STAT3 gene expression. Dupilumab is a monoclonal antibody that targets the IL-4α receptor and improves the symptoms of atopic dermatitis by inhibiting IL-4 and IL-13. We used dupilumab to treat severe dermatitis in a patient with STAT3-HIES and achieved satisfactory results.

高免疫球蛋白 E 综合征(HIES)是一种原发性免疫缺陷病,以特应性皮炎、反复皮肤和肺部感染以及血清免疫球蛋白 E 水平显著升高为特征。STAT3基因的常染色体显性和功能缺失致病变异是该病最常见的病因,研究表明,在STAT3基因表达显性阴性突变的患者中,IL-4受体(IL-4R)的存在是上调的。杜匹鲁单抗是一种针对 IL-4α 受体的单克隆抗体,可通过抑制 IL-4 和 IL-13 改善特应性皮炎的症状。我们使用杜匹单抗治疗了一名 STAT3-HIES 患者的严重皮炎,并取得了满意的效果。
{"title":"The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis.","authors":"Weifeng Li, Qiqi Qi, Weipeng Wang, Dongqin Li","doi":"10.5415/apallergy.0000000000000121","DOIUrl":"10.5415/apallergy.0000000000000121","url":null,"abstract":"<p><p>Hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease characterized by atopic dermatitis, recurrent skin and lung infections, and significantly elevated serum immunoglobulin E levels. Autosomal dominant and loss-of-function pathogenic variants in the <i>STAT3</i> gene are the most common causes of the disease and studies have shown that the presence of IL-4 receptor (IL-4R) is upregulated in patients with dominant-negative mutations in the <i>STAT3</i> gene expression. Dupilumab is a monoclonal antibody that targets the IL-4α receptor and improves the symptoms of atopic dermatitis by inhibiting IL-4 and IL-13. We used dupilumab to treat severe dermatitis in a patient with STAT3-HIES and achieved satisfactory results.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"39-41"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective observational study correlating possible novel biomarkers with disease severity and antihistamine response in chronic spontaneous urticaria. 一项前瞻性观察研究,将可能的新型生物标记物与慢性自发性荨麻疹的疾病严重程度和抗组胺药反应相关联。
IF 1.7 Q3 ALLERGY Pub Date : 2024-03-01 Epub Date: 2024-01-11 DOI: 10.5415/apallergy.0000000000000132
Divya Bhatia, Hitaishi Mehta, Anuradha Bishnoi, Niharika Srivastava, Keshavamurthy Vinay, Davinder Parsad, Muthu Sendhil Kumaran

Background: Role of complement fraction 5a (C5a), interleukin (IL)-9, and apolipoprotein (apo) A-IV as biomarkers of disease severity and antihistamine response in chronic spontaneous urticaria (CSU) remains elusive.

Objective: To identify the role of C5a, IL-9, and apo A-IV as potential biomarkers in predicting disease severity and antihistamine response in CSU patients.

Methods: This was a prospective observational study of 95 patients and 42 controls. Serum analysis of C5a, IL-9, and apo A-IV was done using enyzme linked immunosorbent assay kits. Also, serum IgE and anti-thyroid peroxidase (TPO) levels were assessed in all patients. All patients were started on oral levocetirizine 5 mg at baseline and dose was titrated upwards to maximum of 20 mg based on response. Patients were categorized into antihistamine responders or nonresponders as per their disease response. Serological markers, serum IgE, and anti-TPO were correlated with baseline disease severity and antihistamine response.

Results: C5a levels were significantly higher in cases as compared to controls (P = 0.004). Significantly higher IL-9 levels were observed in antihistamine responders than nonresponders (P = 0.008). Baseline urticaria severity demonstrated a statistically significant positive and negative correlations with IL-9 (ρ = 0.277, P = 0.007) and apo A-IV (ρ = -0.271, P = 0.008) levels, respectively. Levels of serum IgE (P = 0.031) and anti-TPO (P = 0.039) were significantly higher in antihistamine nonresponders compared to responders.

Conclusions: IL-9 and apo A-IV might be potential novel biomarkers to predict urticaria severity. Higher IL-9 might be a predictor of antihistamine response. Elevated anti-TPO and serum IgE might predict poor antihistamine response.

背景:补体5a (C5a)、白细胞介素(IL)-9和载脂蛋白(apolipoprotein) A-IV作为慢性自发性荨麻疹(CSU)疾病严重程度和抗组胺反应的生物标志物的作用仍未确定:确定C5a、IL-9和载脂蛋白A-IV作为潜在生物标志物在预测慢性自发性荨麻疹患者疾病严重程度和抗组胺反应中的作用:这是一项前瞻性观察研究,共有 95 名患者和 42 名对照者参加。使用酶联免疫吸附测定试剂盒对血清中的C5a、IL-9和载脂蛋白A-IV进行分析。此外,还对所有患者的血清 IgE 和抗甲状腺过氧化物酶 (TPO) 水平进行了评估。所有患者开始口服 5 毫克左西替利嗪(levocetirizine),然后根据反应调整剂量,最大剂量为 20 毫克。根据患者的疾病反应,将其分为抗组胺反应者和无反应者。血清标志物、血清 IgE 和抗TPO 与基线疾病严重程度和抗组胺药反应相关:结果:与对照组相比,病例的 C5a 水平明显更高(P = 0.004)。抗组胺药应答者的 IL-9 水平明显高于无应答者(P = 0.008)。基线荨麻疹严重程度分别与 IL-9 (ρ = 0.277, P = 0.007) 和载脂蛋白 A-IV (ρ = -0.271, P = 0.008) 水平呈显著的正相关和负相关。抗组胺药无应答者的血清IgE(P = 0.031)和抗TPO(P = 0.039)水平明显高于有反应者:结论:IL-9和载脂蛋白A-IV可能是预测荨麻疹严重程度的潜在新型生物标志物。结论:IL-9和载脂蛋白A-IV可能是预测荨麻疹严重程度的新生物标志物。抗TPO和血清IgE升高可能预示抗组胺药反应不佳。
{"title":"A prospective observational study correlating possible novel biomarkers with disease severity and antihistamine response in chronic spontaneous urticaria.","authors":"Divya Bhatia, Hitaishi Mehta, Anuradha Bishnoi, Niharika Srivastava, Keshavamurthy Vinay, Davinder Parsad, Muthu Sendhil Kumaran","doi":"10.5415/apallergy.0000000000000132","DOIUrl":"10.5415/apallergy.0000000000000132","url":null,"abstract":"<p><strong>Background: </strong>Role of complement fraction 5a (C5a), interleukin (IL)-9, and apolipoprotein (apo) A-IV as biomarkers of disease severity and antihistamine response in chronic spontaneous urticaria (CSU) remains elusive.</p><p><strong>Objective: </strong>To identify the role of C5a, IL-9, and apo A-IV as potential biomarkers in predicting disease severity and antihistamine response in CSU patients.</p><p><strong>Methods: </strong>This was a prospective observational study of 95 patients and 42 controls. Serum analysis of C5a, IL-9, and apo A-IV was done using enyzme linked immunosorbent assay kits. Also, serum IgE and anti-thyroid peroxidase (TPO) levels were assessed in all patients. All patients were started on oral levocetirizine 5 mg at baseline and dose was titrated upwards to maximum of 20 mg based on response. Patients were categorized into antihistamine responders or nonresponders as per their disease response. Serological markers, serum IgE, and anti-TPO were correlated with baseline disease severity and antihistamine response.</p><p><strong>Results: </strong>C5a levels were significantly higher in cases as compared to controls (<i>P</i> = 0.004). Significantly higher IL-9 levels were observed in antihistamine responders than nonresponders (<i>P</i> = 0.008). Baseline urticaria severity demonstrated a statistically significant positive and negative correlations with IL-9 (<i>ρ</i> = 0.277, <i>P</i> = 0.007) and apo A-IV (<i>ρ</i> = -0.271, <i>P</i> = 0.008) levels, respectively. Levels of serum IgE (<i>P</i> = 0.031) and anti-TPO (<i>P</i> = 0.039) were significantly higher in antihistamine nonresponders compared to responders.</p><p><strong>Conclusions: </strong>IL-9 and apo A-IV might be potential novel biomarkers to predict urticaria severity. Higher IL-9 might be a predictor of antihistamine response. Elevated anti-TPO and serum IgE might predict poor antihistamine response.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"5-11"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Blomia tropicalis-specific immunoglobulin epsilon profiles with family history of atopy in a Filipino population. 菲律宾人口中热带布洛莫氏菌特异性免疫球蛋白ε谱与家族过敏史的相关性。
IF 1.6 Q3 ALLERGY Pub Date : 2024-03-01 Epub Date: 2024-01-11 DOI: 10.5415/apallergy.0000000000000133
Chanie Y Patanindagat, Jamie Ezra B Tarun, Ryla Jasmine T Pajaro, Jhon Jerald D Pintucan, Patricia Nichole M Quilang, Maureen B Sabit, John Donnie A Ramos

Background: House dust mites are the major source of indoor allergens in the tropical and subtropical regions with Blomia tropicalis (Bt) allergens as one of the leading causative agents of sensitization among patients from the tropics. Despite the clinical importance of Bt in various populations, its allergenicity remains unclear among Filipino allergic patients.

Objective: This study determined the sensitization profiles of allergic Filipinos against Bt allergens and its correlation with atopy.

Methods: Total immunoglobulin epsilon (IgE) (n = 960), Bt-specific IgE (n = 247), and Blomia tropicalis 5 (Blo t 5)-specific IgE (n = 87) profiles of allergic and nonallergic subjects were measured through enzyme-linked immunosorbent assay (ELISA). Point-biserial correlation coefficient was used to determine the association between Bt-specific IgE levels and selected demographics. Inhibition ELISA was performed to measure the inhibition capacity of recombinant Blo t 5 (rBlo t 5) against Bt allergen extracts.

Results: Mean total IgE levels of allergic cases (n = 171) were significantly higher (P < 0.001) compared to the mean IgE levels of nonallergic controls (n = 76). Among allergic subjects, 58% were sensitized to Blo t extract and 80% of which were sensitized to rBlo t 5 allergen. A positive correlation was observed between Bt-specific IgE and family history of atopic disease (P = 0.031). Inhibition assay revealed that 54% mean reactivity of 7 plasma samples was caused by rBlo t 5, validating that rBlo t 5 is a major allergen in Bt.

Conclusions: This study has shown the importance of Bt as an allergen source that sensitizes atopic Filipino subjects. Hence, inclusion of Bt allergen extract and rBlo t 5 in the panel for allergy diagnosis and immunotherapy in Filipino populations is strongly recommended.

背景:在热带和亚热带地区,室内尘螨是室内过敏原的主要来源,而热带布洛米亚虫(Blomia tropicalis,Bt)过敏原是导致热带地区患者过敏的主要致敏原之一。尽管 Bt 在不同人群中具有重要的临床意义,但其在菲律宾过敏症患者中的致敏性仍不明确:本研究确定了菲律宾过敏症患者对 Bt 过敏原的致敏特征及其与过敏症的相关性:方法:通过酶联免疫吸附试验(ELISA)测定了过敏性和非过敏性受试者的总免疫球蛋白epsilon(IgE)(960人)、Bt特异性IgE(247人)和Blomia tropicalis 5(Blo t 5)特异性IgE(87人)。采用点-阶梯相关系数确定 Bt 特异性 IgE 水平与选定人口统计学特征之间的关联。采用抑制酶联免疫吸附试验测定重组 Blo t 5(rBlo t 5)对 Bt 过敏原提取物的抑制能力:结果:过敏病例(n = 171)的平均总 IgE 水平明显高于非过敏对照组(n = 76)(P < 0.001)。在过敏受试者中,有 58% 对 Blo t 提取物过敏,其中 80% 对 rBlo t 5 过敏原过敏。Bt 特异性 IgE 与特应性疾病家族史呈正相关(P = 0.031)。抑制测定显示,7 份血浆样本中 54% 的平均反应性是由 rBlo t 5 引起的,这验证了 rBlo t 5 是 Bt 的主要过敏原:本研究表明,Bt 是导致菲律宾特应性受试者过敏的重要过敏原来源。因此,强烈建议将 Bt 过敏原提取物和 rBlo t 5 纳入菲律宾人群过敏诊断和免疫疗法的面板中。
{"title":"Correlation of <i>Blomia tropicalis</i>-specific immunoglobulin epsilon profiles with family history of atopy in a Filipino population.","authors":"Chanie Y Patanindagat, Jamie Ezra B Tarun, Ryla Jasmine T Pajaro, Jhon Jerald D Pintucan, Patricia Nichole M Quilang, Maureen B Sabit, John Donnie A Ramos","doi":"10.5415/apallergy.0000000000000133","DOIUrl":"10.5415/apallergy.0000000000000133","url":null,"abstract":"<p><strong>Background: </strong>House dust mites are the major source of indoor allergens in the tropical and subtropical regions with <i>Blomia tropicalis</i> (Bt) allergens as one of the leading causative agents of sensitization among patients from the tropics. Despite the clinical importance of Bt in various populations, its allergenicity remains unclear among Filipino allergic patients.</p><p><strong>Objective: </strong>This study determined the sensitization profiles of allergic Filipinos against Bt allergens and its correlation with atopy.</p><p><strong>Methods: </strong>Total immunoglobulin epsilon (IgE) (n = 960), Bt-specific IgE (n = 247), and <i>Blomia tropicalis</i> 5 (Blo t 5)-specific IgE (n = 87) profiles of allergic and nonallergic subjects were measured through enzyme-linked immunosorbent assay (ELISA). Point-biserial correlation coefficient was used to determine the association between Bt-specific IgE levels and selected demographics. Inhibition ELISA was performed to measure the inhibition capacity of recombinant Blo t 5 (rBlo t 5) against Bt allergen extracts.</p><p><strong>Results: </strong>Mean total IgE levels of allergic cases (n = 171) were significantly higher (<i>P</i> < 0.001) compared to the mean IgE levels of nonallergic controls (n = 76). Among allergic subjects, 58% were sensitized to Blo t extract and 80% of which were sensitized to rBlo t 5 allergen. A positive correlation was observed between Bt-specific IgE and family history of atopic disease (<i>P</i> = 0.031). Inhibition assay revealed that 54% mean reactivity of 7 plasma samples was caused by rBlo t 5, validating that rBlo t 5 is a major allergen in Bt.</p><p><strong>Conclusions: </strong>This study has shown the importance of Bt as an allergen source that sensitizes atopic Filipino subjects. Hence, inclusion of Bt allergen extract and rBlo t 5 in the panel for allergy diagnosis and immunotherapy in Filipino populations is strongly recommended.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"12-20"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia Pacific Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1